Mycobacterium florentinum pulmonary disease: a case report and review of the literature.

ABSTRACT:

Background

Following the initial description of Mycobacterium florentinum in 2005, very few clinical cases have been reported and the optimal antimicrobial treatment and clinical outcomes are uncertain. Amikacin liposome inhalation suspension (ALIS) has received approval for the treatment of Mycobacterium avium/intracellulare complex (MAC) pulmonary disease. However, there is little experience with its use for infections caused by less common nontuberculous mycobacteria (NTM). Moreover, the awareness of uncommon adverse effects is still limited.

Case presentation

A 69-year-old female patient suffering from nodular bronchiectatic Mycobacterium florentinum pulmonary disease was treated with azithromycin, ethambutol, and rifampicin, administered three times per week. After 13 m

SUBMITTER: Leo F 

PROVIDER: S-EPMC12822083 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature